• Astellas Pharma Inc., of Tokyo, said the FDA approved its supplemental new drug application for the use of Mycamine (micafungin sodium) for injection by intravenous infusion for the treatment of pediatric patients 4 months and older with candidemia, acute disseminated candiasis, Candida peritonitis and abscesses, esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplants.